| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $728,640 | 5 | 100 |
Sells | $0 | 0 | 0 |
| Carter Denise P. | Chief Operating Officer | 1 | $250,000 | 0 | $0 | $250,000 |
| Myers Michael | Chief Executive Officer | 1 | $250,000 | 0 | $0 | $250,000 |
| LANGER DENNIS | director | 1 | $128,640 | 0 | $0 | $128,640 |
| Dunn Gordon | Chief Financial Officer | 1 | $54,999 | 0 | $0 | $54,999 |
| Culverwell Anthony James | director | 1 | $45,000 | 0 | $0 | $45,000 |
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Over the last 12 months, insiders at Quoin Pharmaceuticals, Ltd. have bought $728,640 and sold $0 worth of Quoin Pharmaceuticals, Ltd. stock.
On average, over the past 5 years, insiders at Quoin Pharmaceuticals, Ltd. have bought $406,349 and sold $217 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Carter Denise P. (Chief Operating Officer) — $250,000. Myers Michael (Chief Executive Officer) — $250,000. LANGER DENNIS (director) — $128,640.
The last purchase of 15,152 shares for transaction amount of $128,640 was made by LANGER DENNIS (director) on 2025‑10‑14.
| 2025-10-14 | LANGER DENNIS | director | 15,152 1.5567% | $8.49 | $128,640 | +0.53% | ||
| 2024-12-23 | Myers Michael | Chief Executive Officer | 555,556 9.5152% | $0.45 | $250,000 | -51.09% | ||
| 2024-12-23 | Carter Denise P. | Chief Operating Officer | 555,556 9.5152% | $0.45 | $250,000 | -51.09% | ||
| 2024-12-23 | Dunn Gordon | Chief Financial Officer | 122,221 2.0933% | $0.45 | $54,999 | -51.09% | ||
| 2024-12-23 | Culverwell Anthony James | director | 100,000 1.7127% | $0.45 | $45,000 | -51.09% | ||
| 2024-09-10 | Dunn Gordon | Chief Financial Officer | 20,000 0.5852% | $0.81 | $16,200 | -57.31% | ||
| 2024-09-09 | Dunn Gordon | Chief Financial Officer | 8,856 0.1833% | $0.79 | $7,005 | -68.84% | ||
| 2024-09-09 | Dunn Gordon | Chief Financial Officer | 4,000 0.0838% | $0.80 | $3,200 | -68.84% | ||
| 2024-09-04 | Myers Michael | Chief Executive Officer | 37,094 0.8928% | $0.77 | $28,421 | -62.50% | ||
| 2024-09-04 | Carter Denise P. | Chief Operating Officer | 31,813 0.7825% | $0.78 | $24,912 | -62.50% | ||
| 2024-09-03 | Carter Denise P. | Chief Operating Officer | 5,922 0.1416% | $0.65 | $3,825 | -55.81% | ||
| 2024-09-03 | Myers Michael | Chief Executive Officer | 800 0.0183% | $0.62 | $495 | -55.81% | ||
| 2024-06-07 | Sale | LANGER DENNIS | director | 297 0.008% | $0.73 | $217 | -22.34% |
| Myers Michael | Chief Executive Officer | 602808 102.4894% | $9.07M | 3 | 0 | <0.0001% |
| Carter Denise P. | Chief Operating Officer | 602648 102.4622% | $9.07M | 3 | 0 | <0.0001% |
| Dunn Gordon | Chief Financial Officer | 151077 25.6861% | $2.27M | 4 | 0 | <0.0001% |
| Culverwell Anthony James | director | 100317 17.0559% | $1.51M | 1 | 0 | |
| LANGER DENNIS | director | 15153 2.5763% | $228,052.65 | 1 | 1 |
$8,253,997 | 122 | -53.40% | $10.39M | |
$1,848,072 | 66 | -14.67% | $9.2M | |
$13,664,154 | 40 | -70.35% | $7.07M | |
$63,749,694 | 24 | -12.24% | $9.13M | |
$37,197,670 | 19 | -48.42% | $10.29M | |
$1,556,551 | 15 | -25.43% | $7.3M | |
$945,055 | 14 | -8.25% | $8.29M | |
$742,412 | 14 | -50.36% | $8.41M | |
$389,864 | 11 | 12.52% | $8.77M | |
$188,726 | 11 | -28.87% | $9.81M | |
$309,830 | 10 | -55.78% | $8.43M | |
$120,379 | 10 | -24.48% | $7.59M | |
$3,885,120 | 9 | -38.33% | $10.21M | |
$159,974 | 7 | -18.60% | $7.46M | |
Quoin Pharmaceuticals, Ltd. (QNRX) | $84,058 | 7 | -61.66% | $8.85M |
$7,268,979 | 7 | -48.44% | $10.2M | |
$183,033 | 6 | -38.07% | $9.84M | |
$1,057,000 | 3 | 5.27% | $9.12M | |
$28,395 | 3 | 3.48% | $8.2M |
| Increased Positions | <1 | +10% | 38 | +1.5% |
| Decreased Positions | 4 | -40% | 1,084 | -42.71% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 2 | Sold Out | 923 | Sold Out |
| Total Postitions | 7 | -30% | 1,492 | -41.21% |
| Rhumbline Advisers | $15.00 | <0.01% | 1,210 | -32 | -2.58% | 2025-09-30 |
| Gamma Investing Llc | $3.00 | <0.01% | 278 | +38 | +15.83% | 2025-09-30 |
| Sbi Securities Co., Ltd. | $0 | 0% | 2 | 0 | 0% | 2025-09-30 |
| Ubs Group Ag | $0 | 0% | 1 | -129 | -99.23% | 2025-09-30 |
| Huntington National Bank | $0 | 0% | 1 | 0 | 0% | 2025-09-30 |
| Morgan Stanley | $0 | 0% | 0 | -206 | Sold Out | 2025-09-30 |
| Raymond James Financial Inc | $0 | 0% | 0 | -717 | Sold Out | 2025-09-30 |